bstract
BACKGROUND: As an inhibitor of programmed death-1 (PD-1) protein, nivolumab has been shown to be effective in various cancers. We thus conducted this meta-analysis to compare the relative efficacy of nivolumab vs docetaxel-based chemotherapy as a second-line treatment for previously treated advanced non-small cell lung cancer (NSCLC).
METHODS: Relevant studies were identified through searches of databases and conference proceedings. Progression-free survival (PFS), overall survival (OS), drug responses, and adverse effects (AEs) were assessed as the primary endpoints.
RESULTS: After screening, we included six studies (949 patients) in the final analysis. Nivolumab showed better efficacy in terms of the PFS (hazard ratios [HR]: 0.70, P = 0.03), OS (HR: 0.70, P < 0.00001),< 0.00001)
CONCLUSIONS: For advanced NSCLC, nivolumab is a better therapy in terms of both anti-tumor efficacy and safety than docetaxel-based chemotherapy. More high-quality randomized controlled trials are needed to confirm these results.
PMID: 30628185 [PubMed - indexed for MEDLINE]
28 March 2020
11:12
Cancer & Heart (Cardio-Oncology, Cardiotoxicity, TEV)
Photo
Not included, change data exporting settings to download.
256×256, 6.0 KB
11:12
In reply to this message
pubmed: ctoall&ca or conall
Mitochondrial Determinants of Doxorubicin-Induced Cardiomyopathy.
Related Articles
Mitochondrial Determinants of Doxorubicin-Induced Cardiomyopathy.
Circ Res. 2020 Mar 27;126(7):926-941
Authors: Wallace KB, Sardão VA, Oliveira PJ
No comments:
Post a Comment
اكتب تعليق حول الموضوع